IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v17y2020i20p7535-d429300.html
   My bibliography  Save this article

Misalignment of Stakeholder Incentives in the Opioid Crisis

Author

Listed:
  • Alireza Boloori

    (Department of Statistics and Probability, Michigan State University, East Lansing, MI 48824, USA
    Department of Family Medicine, Michigan State University, Grand Rapids, MI 49503, USA)

  • Bengt B. Arnetz

    (Department of Family Medicine, Michigan State University, Grand Rapids, MI 49503, USA)

  • Frederi Viens

    (Department of Statistics and Probability, Michigan State University, East Lansing, MI 48824, USA)

  • Taps Maiti

    (Department of Statistics and Probability, Michigan State University, East Lansing, MI 48824, USA)

  • Judith E. Arnetz

    (Department of Family Medicine, Michigan State University, Grand Rapids, MI 49503, USA)

Abstract

The current opioid epidemic has killed more than 446,000 Americans over the past two decades. Despite the magnitude of the crisis, little is known to what degree the misalignment of incentives among stakeholders due to competing interests has contributed to the current situation. In this study, we explore evidence in the literature for the working hypothesis that misalignment rooted in the cost, quality, or access to care can be a significant contributor to the opioid epidemic. The review identified several problems that can contribute to incentive misalignment by compromising the triple aims (cost, quality, and access) in this epidemic. Some of these issues include the inefficacy of conventional payment mechanisms in providing incentives for providers, practice guidelines in pain management that are not easily implementable across different medical specialties, barriers in adopting multi-modal pain management strategies, low capacity of providers/treatments to address opioid/substance use disorders, the complexity of addressing the co-occurrence of chronic pain and opioid use disorders, and patients’ non-adherence to opioid substitution treatments. In discussing these issues, we also shed light on factors that can facilitate the alignment of incentives among stakeholders to effectively address the current crisis.

Suggested Citation

  • Alireza Boloori & Bengt B. Arnetz & Frederi Viens & Taps Maiti & Judith E. Arnetz, 2020. "Misalignment of Stakeholder Incentives in the Opioid Crisis," IJERPH, MDPI, vol. 17(20), pages 1-19, October.
    • Handle: RePEc:gam:jijerp:v:17:y:2020:i:20:p:7535-:d:429300
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/17/20/7535/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/17/20/7535/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Van Zee, A., 2009. "The promotion and marketing of oxycontin: Commercial triumph, public health tragedy," American Journal of Public Health, American Public Health Association, vol. 99(2), pages 221-227.
    2. Kristen S Lee & Lisa Quintiliani & Alexandra Heinz & Natrina L Johnson & Ziming Xuan & Ve Truong & Karen E Lasser, 2020. "A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program," PLOS ONE, Public Library of Science, vol. 15(2), pages 1-10, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. William Encinosa & Didem Bernard & Thomas M. Selden, 2022. "Opioid and non-opioid analgesic prescribing before and after the CDC’s 2016 opioid guideline," International Journal of Health Economics and Management, Springer, vol. 22(1), pages 1-52, March.
    2. McGranahan, David A. & Parker, Timothy S., 2021. "The Opioid Epidemic: A Geography in Two Phases," USDA Miscellaneous 310390, United States Department of Agriculture.
    3. Anne Case & Angus Deaton, 2017. "Mortality and Morbidity in the 21st Century," Brookings Papers on Economic Activity, Economic Studies Program, The Brookings Institution, vol. 48(1 (Spring), pages 397-476.
    4. Shannon M. Monnat, 2022. "Demographic and Geographic Variation in Fatal Drug Overdoses in the United States, 1999–2020," The ANNALS of the American Academy of Political and Social Science, , vol. 703(1), pages 50-78, September.
    5. McGranahan, David & Parker, Timothy, 2021. "The Opioid Epidemic: A Geography in Two Phases," Economic Research Report 327197, United States Department of Agriculture, Economic Research Service.
    6. Jessica Y. Ho, 2019. "The Contemporary American Drug Overdose Epidemic in International Perspective," Population and Development Review, The Population Council, Inc., vol. 45(1), pages 7-40, March.
    7. Shiyu Zhang & Daniel Guth, 2021. "The OxyContin Reformulation Revisited: New Evidence From Improved Definitions of Markets and Substitutes," Papers 2101.01128, arXiv.org, revised Jan 2021.
    8. Yang, Tse-Chuan & Shoff, Carla & Kim, Seulki, 2022. "Social isolation, residential stability, and opioid use disorder among older Medicare beneficiaries: Metropolitan and non-metropolitan county comparison," Social Science & Medicine, Elsevier, vol. 292(C).
    9. Graham, Francis W. & de New, Sonja C. & Nielsen, Suzanne & Petrie, Dennis, 2023. "Revisiting the OxyContin Reformulation: The Role of Licit Substitutes," IZA Discussion Papers 16653, Institute of Labor Economics (IZA).
    10. Claudio Deiana & Ludovica Giua & Roberto Nisticò, 2019. "The Economics Behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US," CSEF Working Papers 525, Centre for Studies in Economics and Finance (CSEF), University of Naples, Italy, revised 13 May 2019.
    11. Glei, Dana A. & Stokes, Andrew & Weinstein, Maxine, 2020. "Changes in mental health, pain, and drug misuse since the mid-1990s: Is there a link?," Social Science & Medicine, Elsevier, vol. 246(C).
    12. Strulik, Holger, 2021. "From pain patient to junkie: An economic theory of painkiller consumption and its impact on wellbeing and longevity," Journal of Health Economics, Elsevier, vol. 76(C).
    13. Sacks, Daniel W. & Hollingsworth, Alex & Nguyen, Thuy & Simon, Kosali, 2021. "Can policy affect initiation of addictive substance use? Evidence from opioid prescribing," Journal of Health Economics, Elsevier, vol. 76(C).
    14. Carolina Arteaga Cabrales & Victoria Barone, 2021. "The Opioid Epidemic: Causes and Consequences," Working Papers tecipa-698, University of Toronto, Department of Economics.
    15. William N. Evans & Ethan M. J. Lieber & Patrick Power, 2019. "How the Reformulation of OxyContin Ignited the Heroin Epidemic," The Review of Economics and Statistics, MIT Press, vol. 101(1), pages 1-15, March.
    16. Bardwell, Geoff & Small, Will & Lavalley, Jennifer & McNeil, Ryan & Kerr, Thomas, 2021. "“People need them or else they're going to take fentanyl and die”: A qualitative study examining the ‘problem’ of prescription opioid diversion during an overdose epidemic," Social Science & Medicine, Elsevier, vol. 279(C).
    17. Johanna Catherine Maclean & Justine Mallatt & Christopher J. Ruhm & Kosali Simon, 2022. "The Opioid Crisis, Health, Healthcare, and Crime: A Review of Quasi-Experimental Economic Studies," The ANNALS of the American Academy of Political and Social Science, , vol. 703(1), pages 15-49, September.
    18. Sheryl Spithoff & Pamela Leece & Frank Sullivan & Nav Persaud & Peter Belesiotis & Liane Steiner, 2020. "Drivers of the opioid crisis: An appraisal of financial conflicts of interest in clinical practice guideline panels at the peak of opioid prescribing," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-15, January.
    19. Janet Currie & Hannes Schwandt, 2021. "The Opioid Epidemic Was Not Caused by Economic Distress but by Factors That Could Be More Rapidly Addressed," The ANNALS of the American Academy of Political and Social Science, , vol. 695(1), pages 276-291, May.
    20. Alexander Ahammer & Martin Halla, 2022. "The intergenerational persistence of opioid dependence: Evidence from administrative data," Health Economics, John Wiley & Sons, Ltd., vol. 31(11), pages 2425-2444, November.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:20:p:7535-:d:429300. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.